Browse the evidence

GLP-1RAs confer cardiovascular protection by reducing the risk of major adverse cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with established cardiovascular disease and obesity.

If you have obesity and existing heart disease, GLP-1 receptor agonists like semaglutide can significantly reduce your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of whether you have diabetes, making these medications a crucial part of cardiovascular risk management for obese patients.

Metformin provides modest weight loss (average ~2.1 kg/year) and improves insulin sensitivity, making it a first-line treatment for T2DM, though it is not FDA-approved specifically for weight loss.

Metformin is a standard first-line medication for Type 2 Diabetes. It helps control blood sugar and may lead to modest weight loss (about 2 kg per year), but it is not a powerful weight-loss drug. It is generally safe and well-tolerated, though some people experience gastrointestinal side effects.

GLP-1 receptor agonists (e.g., semaglutide) and GLP-2 analogs (e.g., teduglutide) are FDA-approved interventions that treat obesity and short bowel syndrome by mimicking enteroendocrine cell hormone secretion.

If you have obesity or short bowel syndrome, talk to your doctor about GLP-1 based medications like semaglutide. These are FDA-approved treatments that mimic your gut's natural hormones to help with weight loss or nutrient absorption. They are not lifestyle fixes but medical interventions for specific conditions.

GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) provide cardiovascular and kidney protection in patients with chronic kidney disease (CKD) and overweight/obesity, with or without type 2 diabetes (T2DM), by reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression.

If you have chronic kidney disease and are overweight or obese, ask your doctor about GLP-1 receptor agonists like semaglutide or liraglutide. These medications are not just for weight loss; they have been proven to protect your heart and kidneys, even if you do not have diabetes. They are available in both daily and weekly formulations, and sometimes orally, making them a versatile option for managing your overall metabolic health.

Semaglutide (2.4 mg weekly) produces a clinically significant reduction in systolic blood pressure (approx. 4.8 mmHg) and diastolic blood pressure (approx. 2.5 mmHg) in adults with obesity but without diabetes, even among those with normotensive baseline blood pressure.

If you have obesity and high blood pressure (or even normal blood pressure), semaglutide 2.4 mg taken once weekly can significantly lower your blood pressure. This benefit exists even if you are not currently diagnosed with hypertension. It is a weight-centric approach to managing blood pressure.

Insulin therapy is associated with significant weight gain (mean 4.3 kg) in patients with Type 2 Diabetes, driven by caloric conservation, anabolic effects, and defensive eating to avoid hypoglycemia.

If you are on insulin and gaining weight, know that this is a known side effect caused by how insulin stores energy and your body's response to prevent low blood sugar. Discuss switching to or adding GLP-1 agonists with your doctor, as they can help with weight loss while managing blood sugar.

A 12-week treatment with dulaglutide prevents post-cessation weight gain in the short term (12 weeks), but this benefit is lost after discontinuation, resulting in similar weight gain to placebo at 52 weeks.

Dulaglutide can help you avoid gaining weight during your first 12 weeks of quitting smoking. However, once you stop the injections, you will likely gain weight similar to someone not taking the drug. To maintain weight loss, you may need to stay on the medication longer than 12 weeks.

GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), including cardiovascular mortality, myocardial infarction, and stroke, in patients with type 2 diabetes and high cardiovascular risk.

If you have Type 2 Diabetes and existing heart disease or high risk, GLP-1 receptor agonists (like Semaglutide or Liraglutide) are proven to lower your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of weight loss in some cases, though weight loss often accompanies it. Discuss these options with your doctor, especially if you are at high risk.

Treatment with GLP-1 RAs or GIP/GLP-1 RAs significantly reduces the risk of myocardial infarction (MI) and nonfatal MI in overweight or obese adults without diabetes, but does not significantly reduce the risk of stroke.

In non-diabetic overweight or obese adults, GLP-1 and GIP/GLP-1 receptor agonists significantly lower the risk of heart attacks (myocardial infarction), including nonfatal ones. However, these drugs did not show a significant reduction in stroke risk in this specific population, unlike some findings in diabetic patients.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) by approximately 14% in patients with type 2 diabetes, independent of glucose-lowering effects.

If you have Type 2 Diabetes and are at risk for heart disease, GLP-1 medications (like semaglutide or liraglutide) are proven to significantly lower your risk of heart attack, stroke, and cardiovascular death. These benefits exist even beyond just lowering blood sugar. While injections can cause stomach upset, starting with a low dose and increasing slowly usually manages this. Oral options are also available for some drugs.

GLP-1 receptor agonists significantly reduce the risk of major adverse cardiovascular events (MACE), cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure in both patients with type 2 diabetes and overweight/obese patients without diabetes.

If you have type 2 diabetes or are overweight/obese with cardiovascular risk factors, GLP-1 receptor agonists (like semaglutide or liraglutide) can significantly lower your risk of heart attacks, strokes, and heart failure hospitalizations, regardless of whether you have diabetes. These benefits are seen with both daily and weekly formulations, and oral options exist.

GLP-1 receptor agonists (semaglutide, tirzepatide) induce high rates of reversion to normoglycemia in individuals with prediabetes, but these benefits are largely lost upon discontinuation of the therapy.

GLP-1 medications like semaglutide are highly effective at reversing prediabetes, with nearly all users returning to normal blood sugar levels while taking the drug. However, stopping the medication usually leads to weight regain and the return of prediabetes. Discuss with your doctor whether this is a short-term reset or a long-term management strategy for you.

Semaglutide 2.4 mg weekly reduces major adverse cardiovascular events (MACE) by 20% in people with BMI ≥27 kg/m² and pre-existing cardiovascular disease, independent of diabetes status.

If you are overweight (BMI 27+) and have heart disease, ask your doctor about semaglutide. It has been shown to reduce the risk of heart attack, stroke, or death from heart causes by 20%. This benefit exists even if you don't have diabetes.

Discontinuation of GLP-1 based therapies leads to significant weight regain, indicating that obesity requires chronic management rather than short-term treatment.

If you stop taking GLP-1 medications like semaglutide or tirzepatide, you will likely regain the weight you lost. These drugs treat obesity as a chronic condition, meaning they are intended for long-term use to maintain weight loss.

Obesity medications (OMs) such as semaglutide and tirzepatide provide benefits for adiposity-related conditions independent of weight reduction.

If you are considering obesity medications, ask your doctor about their potential benefits beyond weight loss, such as reducing cardiovascular risk or improving sleep apnea. These benefits may be significant even if weight loss is modest.

Semaglutide (GLP-1 receptor agonist) significantly reduces major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes and established cardiovascular disease.

If you have type 2 diabetes and existing heart disease or high risk, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to significantly reduce the risk of heart attacks, strokes, and cardiovascular death.

Semaglutide slows the progression of chronic kidney disease (CKD) and reduces major kidney disease events in patients with type 2 diabetes.

If you have type 2 diabetes and chronic kidney disease, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to significantly slow the progression of kidney disease and reduce the risk of major kidney events.

Tirzepatide significantly improves all major lipid profile markers (HDL-C, LDL-C, Total Cholesterol, and Triglycerides) in a dose-dependent manner across patients with type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, Tirzepatide (5mg, 10mg, or 15mg) significantly improves your cholesterol and triglyceride levels in a dose-dependent way. It raises 'good' HDL cholesterol and lowers 'bad' LDL cholesterol and triglycerides more effectively than placebo, and potentially better than other GLP-1 drugs. The benefits increase with higher doses (up to 15mg) over treatment periods of 27-72 weeks. Be aware of injection site reactions and high costs, but the metabolic improvements are robust.

GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and slow kidney function decline in patients with type 2 diabetes, with benefits extending to those with established chronic kidney disease (CKD).

If you have Type 2 Diabetes and kidney issues or heart disease, GLP-1 medications (like Ozempic, Trulicity, or Victoza) are now considered essential, not just optional. They protect your heart and kidneys beyond just lowering blood sugar. Start with a low dose to avoid stomach upset, and work with your doctor to find the right strength. These are often covered by insurance for kidney/heart protection.

Increased BMI causally increases the risk of coronary artery disease and heart failure, independent of traditional risk factors like blood pressure and diabetes, though these factors mediate a significant portion of the risk.

High body weight directly harms the heart, even if your blood pressure and cholesterol are managed with medication. This is because excess fat tissue itself causes inflammation and stress on the cardiovascular system. Losing weight reduces this independent risk, protecting your heart beyond just improving numbers like blood pressure.

Central adiposity (measured by waist-to-hip ratio) is a stronger predictor of cardiometabolic risk than overall body mass index (BMI), primarily due to visceral fat and limited subcutaneous storage capacity leading to ectopic lipid deposition.

Don't just look at the scale. Where you store fat is critical. Excess fat around your waist (visceral fat) is biologically active and releases harmful substances that lead to diabetes and heart disease, even if your overall weight is normal. Measuring your waist circumference is a better indicator of risk than BMI alone.

GLP-1 receptor agonists (GLP-1RAs) provide significant cardiorenal protection in patients with type 2 diabetes and obesity, reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression independent of, or in addition to, glycemic control and weight loss.

If you have type 2 diabetes or obesity with heart/kidney risks, GLP-1 medications (like semaglutide or liraglutide) are highly effective. They don't just lower blood sugar; they significantly reduce the risk of heart attacks, strokes, and kidney failure. While they can cause temporary stomach upset, the long-term benefits for your heart and kidneys are substantial and proven by large clinical trials. Discuss these options with your doctor, especially if you have existing heart or kidney conditions.

Intensive blood pressure control (target <130/80 mmHg) reduces stroke and macroalbuminuria progression in type 2 diabetes compared to conventional control, without significantly affecting all-cause mortality.

If you have diabetes, aim for a blood pressure target below 130/80 mmHg, especially if you have kidney disease or heart risks. This significantly lowers your risk of stroke and kidney damage. Use home monitoring to get a true average, as clinic readings can be misleading.

Semaglutide significantly improves MASH resolution and reduces liver steatosis and enzymes, but does not significantly improve fibrosis regression, with efficacy increasing at doses ≥2.0 mg/week and durations ≥12 months.

If you have MASH, semaglutide is a strong option to resolve active liver inflammation and reduce liver fat, especially if you can tolerate doses of 2.0 mg/week or higher for at least a year. However, do not expect it to reverse existing liver scarring (fibrosis). The primary benefit is halting active injury and reducing metabolic risk factors like weight and blood sugar, which indirectly protects the liver.